Search GKOS
GLAUKOS Corp
NYSE · CIK 1192448
Last close163.75
Daily change+0.58 (0.36%)
10 Years gain+325.55%
Dividends TTM0
Dividend yield0.00%
Fundamental Analysis
GKOS · STANDARD
SIC 3841 · Surgical & Medical Instruments & Apparatus · Fiscal year end 1231
Fundamental
54.5Momentum
100.0Acceleration
100.0Confidence
84.0Annual Revenue13
Quarterly Revenue56
Annual CFO11
Balance SheetAvailable
RankingEligible
Score Breakdown
Growth19.4 / 25
Quality17.3 / 25
Capital Efficiency0.0 / 20
Balance Sheet15.0 / 15
Shareholder Economics0.0 / 10
Forward Indicators0.0 / 5
Signals
Gross margin expansionGross margin improved by 2.5957 percentage points.
Operating leverageOperating margin improved by 16.908 percentage points.
Net debt reductionNet debt declined versus the comparison period.
Warnings
Receivables anomaly · MEDIUMAccounts receivable growth is materially above revenue growth.
Key Metrics
Revenue Growth TTM54.39%OK
Revenue CAGR 3Y21.51%OK
Gross Margin79.27%OK
Operating Margin-12.83%OK
FCF Marginn/aMISSING
FCF Growthn/aINSUFFICIENT_HISTORY
ROIC-9.88%OK
Incremental Operating Margin 3Y2.49%OK
Net Debt / CFOn/aNOT_MEANINGFUL
Diluted Share Growth 1Y3.85%OK
SBC / Revenuen/aMISSING
SBC / FCFn/aNOT_MEANINGFUL
Financial History
| Period | Revenue | Gross Profit | Operating Income | CFO | FCF | Gross Margin | Op Margin | FCF Margin | ROIC | Shares |
|---|---|---|---|---|---|---|---|---|---|---|
| 2025 FY Dec 31, 2025 | $507.44M | $282.76M | -$199.60M | -$14.79M | -$22.46M | 55.72% | -39.33% | -4.43% | -27.13% | 57.19M |
| 2025 FY Dec 31, 2024 | $383.48M | $289.45M | -$122.37M | -$61.32M | -$67.62M | 75.48% | -31.91% | -17.63% | -20.02% | 52.76M |
| 2025 FY Dec 31, 2023 | $314.71M | $239.14M | -$128.70M | -$57.76M | -$78.01M | 75.99% | -40.89% | -24.79% | -26.11% | 48.43M |
| 2024 FY Dec 31, 2022 | $282.86M | $213.88M | -$82.31M | -$33.08M | -$63.35M | 75.61% | -29.1% | -22.4% | -14.5% | 47.44M |
| 2023 FY Dec 31, 2021 | $294.01M | $227.38M | -$32.87M | $24.71M | -$23.08M | 77.34% | -11.18% | -7.85% | -4.91% | 46.42M |
Formula Trace
| Metric | Value | Formula | Status | Source |
|---|---|---|---|---|
| Revenue TTM | $593.84M | sum latest 4 fiscal quarters Revenue | OK | 0001193125-26-324201, 0001104659-25-104529 |
| Revenue Growth TTM | 54.39% | Revenue_TTM / Revenue_TTM_1Y_ago - 1 | OK | 0001193125-26-324201, 0001104659-25-104529 |
| Revenue CAGR 3Y | 21.51% | (Revenue_current / Revenue_3Y_ago)^(1/3) - 1 | OK | 0001193125-26-061944 |
| Revenue CAGR 5Y | 17.67% | (Revenue_current / Revenue_5Y_ago)^(1/5) - 1 | OK | 0001193125-26-061944 |
| Gross Profit CAGR 3Y | 9.75% | (GrossProfit_current / GrossProfit_3Y_ago)^(1/3) - 1 | OK | 0001193125-26-061944 |
| Operating Income Growth | n/a | OperatingIncome_current / OperatingIncome_prior_year - 1 | INSUFFICIENT_HISTORY | 0001193125-26-324201, 0001104659-25-104529 |
| FCF Growth | n/a | FCF_current / FCF_prior_year - 1 | INSUFFICIENT_HISTORY | derived |
| Revenue Growth Acceleration | n/a | 0.5*(Q0-Q1)+0.3*(Q1-Q2)+0.2*(Q2-Q3) | INSUFFICIENT_HISTORY | derived |
| Gross Profit Acceleration | n/a | 0.5*(Q0-Q1)+0.3*(Q1-Q2)+0.2*(Q2-Q3) | INSUFFICIENT_HISTORY | derived |
| Operating Income Acceleration | n/a | 0.5*(Q0-Q1)+0.3*(Q1-Q2)+0.2*(Q2-Q3) | INSUFFICIENT_HISTORY | derived |
| FCF Acceleration | n/a | 0.5*(Q0-Q1)+0.3*(Q1-Q2)+0.2*(Q2-Q3) | INSUFFICIENT_HISTORY | derived |
| Gross Margin | 79.27% | Gross Profit / Revenue | OK | 0001193125-26-324201, 0001104659-25-104529 |
| Operating Margin | -12.83% | Operating Income / Revenue | OK | 0001193125-26-324201, 0001104659-25-104529 |
| ROIC | -9.88% | NOPAT / Average Invested Capital | OK | 0001193125-26-324201, 0001104659-25-104529 |
| Net Debt / CFO | n/a | Net Debt / CFO | NOT_MEANINGFUL | 0001193125-26-324201 |
| Current Ratio | 5.04x | Current Assets / Current Liabilities | OK | derived |
| Revenue per Diluted Share | $10.10 | Revenue / Diluted Shares | OK | 0001193125-26-324201, 0001104659-25-104529 |
| SBC / FCF | n/a | SBC / FCF | NOT_MEANINGFUL | derived |